[ORIGINAL ARTICLE]

Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients

Isao Ohsawa^{1,2}, Daisuke Honda², Atsuko Hisada^{2,3}, Hiroyuki Inoshita²,
Kisara Onda-Tsueshita², Satoshi Mano², Nobuyuki Sato^{2,4}, Yuya Nakamura¹,
Tatsuo Shimizu^{1,5}, Hiromichi Gotoh¹, Yoshikazu Goto¹,
Yusuke Suzuki² and Yasuhiko Tomino⁶

Abstract:

Objective The present study was designed to identify the clinical characteristics that permit the differential diagnosis of hereditary angioedema (HAE) and mast cell-mediated angioedema (Mast-AE) during the first consultation.

Methods The medical histories and laboratory data of 46 patients with HAE and 41 patients with Mast-AE were compared.

Results The average age of onset in the HAE group (19.8±9.0 years) was significantly lower than that in the Mast-AE group (35.2±12.0 years). The incidence of familial angioedema (AE) in the HAE group (73.9%) was significantly higher than that in the Mast-AE group (9.7%). The frequency of history of AE in the extremities, larynx, or gastrointestinal tract was significantly higher in the HAE group. The frequency of AE episodes of the lips and eyelids was significantly lower in the HAE group. The serum C4 concentration and CH50 titer were lower than the normal limit in 91.3% and 45.6% of the patients in the HAE group, respectively; in Mast-AE group the serum C4 concentration and CH50 titer were significantly lower than the normal limit in 4.8% and 0% of the patients, the difference between the two groups was statistically significant. A C1-inhibitor (C1-INH) activity level of <50% was observed in all of the HAE patients, but none of the Mast-AE patients. The mean serum IgE titer in the HAE group (120.8±130.5 IU/mL) was significantly lower than that in the Mast-AE group (262.2±314.9 IU/mL).

Conclusion The parameters within the patients' medical histories, such as the age at the onset of AE, a family history of AE, and the locations of past AE episodes are critical for the successful diagnosis of the disease. Measurements of the C4 and C1-INH activity are very useful for differential diagnosis of HAE from Mast-AE.

Key words: hereditary angioedema, C1-inhibitor, C4, IgE, mast cell

(Intern Med 57: 319-324, 2018)

(DOI: 10.2169/internalmedicine.8624-16)

Introduction

Hereditary angioedema (HAE) is a rare and potentially

life-threatening disease that results from mutations of the gene encoding C1-inhibitor (C1-INH). The excessive local formation of bradykinin due to the pathological activation of the factor XII-driven plasma contact system is consistently

¹Nephrology Unit, Saiyu Soka Hospital, Japan, ²Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Japan, ³Department of Nephrology, Ikegami General Hospital, Japan, ⁴Deptment of Internal Medicine, Niigata Rosai Hospital, Japan, ⁵Department of Internal Medicine, Saiyu Kawaguchi Clinic, Japan and ⁶Medical Corporation SHOWAKAI, Japan

Received: November 29, 2016; Accepted: June 1, 2017; Advance Publication by J-STAGE: November 1, 2017

Correspondence to Dr. Isao Ohsawa, i.osawa@saiyukai.com

found in patients with acute episodes of HAE (1, 2). Because plasma-derived C1-INH concentrate is available for the first-line treatment of acute HAE attacks, an early diagnosis and prompt treatment are the keys to the best management and have improved patient outcomes. However, European reports indicate a delay between the onset of symptom and the diagnosis, with a mean diagnostic delay of almost 10-15 years (3-6). Our previous Japanese survey also confirmed that the time to the diagnosis (more than 13 years in some cases) was unacceptably long (7). These findings clearly highlight the urgent need for increasing awareness of the clinical symptoms of HAE and for educational campaigns aimed at medical staff in Japan.

Urticaria is a common disorder, which occurs in 20% of individuals at some point during their lives (8). Mast cells play a crucial role in urticaria, and in many cases of angioedema (AE). Mast cell degranulation elicits the release of various mediators, such as histamine, leukotrienes and prostaglandins. The majority of mast cell-mediated AE (Mast-AE) is controlled with the use of anti-histamines or corticosteroids. From the perspective of primary care, approximately 40% of patients with urticaria experience AE (8). On the other hand, 10% of patients have recurrent AE, which is associated with mild urticaria (or the absence of urticaria) (9). Routine laboratory screening tests, independent of the patient's history and physical examination results should be discouraged, since they are of little value in discovering the trigger for Mast-AE reactions (10, 11). Since the true number of patients with Mast-AE might greatly exceed the number of HAE patients, it is crucial to make an accurate differential diagnosis. With this in mind, we aimed to clarify the clinical differences between HAE and Mast-AE.

Materials and Methods

Forty-six (M:F=16:30) HAE patients and 41 (M:F=14:27) Mast-AE patients who were treated at clinics specialized in HAE care at Juntendo University Hospital (Tokyo, Japan) and Saiyu Soka Hospital (Saitama, Japan), were enrolled. All of the patients had confirmed AE. The patients also had introduction letters from their general physicians or photographs of their own AE site(s).

HAE was diagnosed according to the diagnostic criteria described by Agostoni et al. (12) in addition to the Japanese guidelines published in 2010 (13). Within these guidelines, the major clinical criteria are: 1) self-limiting, non-inflammatory subcutaneous AE without major urticarial rash, often recurrent and often lasting for more than 12 hours, 2) self-remitting abdominal pain without a clear organic etiology, often recurrent and often lasting for more than 6 hours, and 3) recurrent laryngeal edema. The minor clinical criteria are a family history of recurrent AE and/or abdominal pain and/or laryngeal edema. The laboratory criteria include: 1) two separate recordings of C1 inhibitor antigenic levels of <50% the normal range in asymptomatic patients of 12

months of age or older who had not recently received a C1-INH infusion, 2) two separate recordings of the C1 inhibitor functional levels of <50% the normal range in asymptomatic patients of 12 months of age or older who had not recently received C1-INH infusion, and 3) a mutation in the C1 inhibitor gene affecting the synthesis and/or function of protein. Using this approach, HAE was diagnosed if there was evidence of one major (points 1-3 above) clinical criterion and one laboratory criterion. AE patients, with the exception of patients with HAE, drug-induced AE and AE with autoimmune disease, were enrolled as Mast-AE patients. We paid special attention to the past symptoms of acute or chronic urticaria, prodromal erythema marginatum, the effectiveness of anti-histamine drugs and/or corticosteroids, estrogen-induced AE and menstruation-related AE (2, 9, 11).

All of the historical physical locations of AE occurrences were recorded for each patient. Blood samples were obtained from the patients at the first consultation for a diagnosis of AE to be made under normal conditions (no swelling and no medication). The following laboratory data were collected: white blood cells (WBC), eosinophils (Eo), red blood cells (RBC), hemoglobin (Hb), hematocrit (Htc), serum creatinine (Cr), total protein (TP), albumin (Alb), immunoglobulin (Ig) G, IgM, IgA, and IgE, C3, C4, total hemolytic complement activity (CH50) and C-reactive protein (CRP) were collected. For the differential diagnosis, the serum concentration of immune complex (IC) (determined using a C1q-binding assay), C1q and cryoglobulin were evaluated, and a genetic analysis of C1-INH was performed in some patients with low functional levels of C1-INH and with no family history of AE. The functional levels of C1-INH were determined using a chromogenic assay (Sysmex, Kobe, Japan). For the differentiation of autoimmune disease, the serum anti-nuclear antibody (ANA) levels were measured. The study was conducted in accordance with the Declaration of Helsinki (1995) and was approved by the Institutional Review Board at Juntendo University and Saiyu Soka Hospital. Written informed consent was obtained from all of the participating patients.

The GraphPad Prism 5 for Windows software program (version 5.04; GraphPad, San Diego, USA) was used for the statistical analysis. Two-sided *p* values of <0.05 were considered to indicate statistical significance. Comparisons between two groups was performed using the Mann-Whitney *U* test. The relationship between categorical variables was analyzed using Fisher's exact test. All of the data were expressed as the mean±standard deviation (SD).

Results

The average age of onset in the HAE group (19.8±9.0 years) was significantly lower than that in the Mast-AE group (35.2±12.0 years) (Table 1). Although the effectiveness of anti-histamine drugs and corticosteroids in treating AE attacks was high in the Mast-AE group, these drugs were also effective in a few HAE patients. We found the

Table 1. Clinical Background.

		HAE	Mast-AE	p
n		46	41	
Male:Female		16:30	14:27	ns**
Age		41.7±13.3	40.6±12.7	ns*
Angioedema				
Age of onset		19.8±9.0	35.2±12.0	p<0.01*
Predromal erythema marginatum	(yes:no)	5:41	0:41	ns**
Effectiveness of anti-histamin drugs	(yes/no)	3/16	28/2	p<0.01**
Effectiveness of corticosteroids	(yes/no)	4/11	10/1	p<0.01**
Estrogen induced (if female)	(yes/no)	4/26	0/27	ns**
Menstruation-related (if female)	(yes/no)	3/27	0/27	ns**
Other medical histories				
Acute or chronic urticaria	(yes:no)	9:37	27:14	p<0.01**
Atopic dermatitis	(yes:no)	4:42	2:39	ns**
Bronchial asthma	(yes:no)	1:45	9:32	p<0.01**
Pollinosis	(yes:no)	9:37	8:33	ns**
Family history of AE	(yes:no)	34:12	4:37	p<0.01**

*Mann-Whitney's U test

**Fisher's exact test

ns: not significant

Table 2. The Number of Patients Having Former Subcutaneous Angioedema.

	Extremities	Face	Lip	Eye lids	Buttocks	Genital
HAE, n (%)	37 (80.4)	18 (39.1)	13 (28.2)	3 (6.5)	5 (10.8)	5 (10.8)
Mast-AE, n (%)	4 (9.7)	8 (19.5)	23 (56.0)	17 (41.4)	1 (2.4)	0 (0.0)
p	<0.01	ns	<0.01	<0.01	ns	ns

Fisher's exact test

ns: not significant

characteristic information about estrogen-induced AE and menstruation-related AE in female HAE patients but there were no statistically significant differences between the HAE and Mast-AE groups. The patients other allergic history (i.e., acute or chronic urticaria and bronchial asthma) were found significantly more frequently in the Mast-AE group. A family history of AE was noted in 73.9% of the patients in the HAE group; the frequency was significantly higher than that in the Mast-AE group (9.7%).

For the analysis of the patients with former AE, the patient population was divided into two parts, patients with subcutaneous AE (Table 2) and patients with submucosal AE (Table 3). Among the subcutaneous cases, AE episodes were observed at the extremities (Fig. 1a) significantly more frequently in the HAE group (80.4%) in comparison to the Mast-AE group (9.7%). AE episodes involving the lips and eyelids were observed significantly less frequently in the HAE group (28.2%, 6.5%) than in the Mast-AE group (56.0%, 41.4%). Genital AE was only observed in the HAE group (5 cases); however, the difference between the groups was not statistically significant. With respect to submucosal

AE, the incidence of laryngeal AE episodes in the HAE group (39.1%) was significantly higher than that in the Mast-AE group (17.0%). Cases of upper air way obstruction (choking) were exclusively observed in the HAE group (6 cases). Three of the six cases had experienced suffocation and required emergency tracheotomy. The frequency of abdominal pain derived from gastrointestinal AE (Fig. 1b) was significantly higher in the HAE group (56.5%) than in the Mast-AE group (12.1%).

There were no significant differences in the WBC, Eo, RBC, Hb, Htc, Cr, TP, Alb, IgG, IgM, IgA, and CRP values of the HAE and Mast-AE groups. The mean IgE titer of the HAE group (120.8±130.5 IU/mL) was significantly lower than that of the Mast-AE group (262.2±314.9 IU/mL) (Table 4). The distribution of the C3, C4, CH50, and C1-INH activity levels is shown in Fig. 2. The mean serum C3 concentration of the HAE group and Mast-AE groups (104.4±23.7 mg/dL and 100.0±17.7 mg/dL, respectively) was similar. A serum C4 concentration of less than normal limit (<14 mg/dL) was seen in 91.3% of the HAE patients and in 4.8% of the Mast-AE patients (Fisher's exact test, p<0.01). In the

Table 3. the Number of Patients Having Former Mucosal Angioedema and Symptoms.

	Oral cavity	Laryngeal	Choking	Abdominal pain
HAE, n (%)	4 (8.6)	18 (39.1)	6 (8.6)	26 (56.5)
Mast-AE, n (%)	5 (12.1)	7 (17.0)	0 (0.0)	5 (12.1)
p	ns	<0.05	<0.05	<0.01

Fisher's exact test

ns: not significant

Figure 1. Pictures of angioedema from patients with hereditary angioedema. a: A 38-year-old female patient. Marked swelling of the left lower limb was observed. b: A 19-year-old female patient. Enhanced computed tomography of the abdomen demonstrated an expanded edematous small intestine (arrow head) and the accumulation of intestinal fluid.

HAE group, 9 of the 46 patients presented with serum levels of C4, which were below the lower limit of quantitation (<2 mg/dL); this was not observed in the Mast-AE group. A CH 50 titer below the normal limit (<25 U/mL) was seen in 45.6% of the HAE patients but not in the Mast-AE patients (Fisher's exact test, $p < 0.01$). In the HAE group, 6 of the 46 patients presented with CH50 titers that were below the lower limit of quantitation (<7 U/mL); this was not the case in the Mast-AE group. A C1-INH activity level of <50% was observed in all (100%) of the HAE patients but none of the Mast-AE patients (Fisher's exact test, $p < 0.01$). In the HAE group, 35 of 46 patients presented with an extremely low C1-INH activity level, which was below the lower limit of quantitation (<25%).

Discussion

HAE is a potentially life-threatening disease caused by mutations in the *SERPING1* gene, which results in the decreased synthesis (type I) or function (type II) of C1-INH (1, 2). The prevalence of HAE is estimated to be 1 case per 50,000-100,000 people, with no reported bias among different ethnic groups (2). It is assumed that there are 2,000 to 3,000 HAE patients in Japan; however, based on the unofficial data collated from case reports in Japan and from several pharmaceutical company databases, it is estimated that 450 patients have been diagnosed in Japan.

The ability to differentially diagnose a patient during the first visit to an outpatient clinic is paramount. Although AE is associated with familiar symptoms, HAE patients typically wait years before being correctly diagnosed (7, 14). Because of the low awareness of HAE among physicians, the correct diagnosis of the disease is complicated by misdiagnosis with the dominant type of AE (Mast-AE). Thus, it is critical to educate doctors and/or medical staff on the specific complaints associated with HAE.

Our results highlight the importance of historical medical data, including the age of AE onset, a family history of AE, and the locations of past AE episodes. With regard to the average age of the patients when the first AE attack, the patients in the HAE group were significantly younger (in adolescence) in comparison to the Mast-AE group. Since our outpatient clinics are for adults, our data may be slightly skewed towards a higher age. In our study, anti-histamine drugs and corticosteroids showed significant efficacy in the Mast-AE group, but were only effective in 9 of 46 patients with HAE combined with acute or chronic urticaria. Thus, the effectiveness of these drugs cannot be used to reliably differentiate between HAE and Mast-AE.

Because an estrogen-responsive element in the promotor region of the factor XII gene is responsible for the exacerbation of AE (2, 9), we only found a history of estrogen-induced AE and menstruation-related AE among the HAE patients.

As previously reported, 75% of HAE patients present with an autosomal dominant inheritance form of disease and 25% of HAE patients present with *de novo* mutations (1, 2). Because our data confirmed the high frequency of autosomal dominant inheritance (73.9%), we can infer that monitoring the family history of AE would be very informative. Hun-

Table 4. Laboratory Data Obtained at the First Consultation.

		HAE	Mast-AE	p
Eosinocyte (μL)		191.3 $\pm$ 267.0	206.3 $\pm$ 223.5	ns*
IgE (IU/mL)		120.8 $\pm$ 130.5	262.2 $\pm$ 314.9	p<0.01*
C3 (mg/dL)		104.4 $\pm$ 23.7	100.0 $\pm$ 17.7	ns*
C4 <14 (mg/dL)	(yes:no)	42:4	2:39	p<0.01**
CH50 <25 (U/mL)	(yes:no)	21:25	0:41	p<0.01**
C1-INH activity <50 (%)	(yes:no)	46:0	0:41	p<0.01**

*Mann-Whitney's U test

**Fisher's exact test

ns: not significant

Figure 2. Dot plots of the complement system parameters. a: The serum levels of C3. b: The serum levels of C4. c: The serum titers of CH50. d: The serum activities of C1-inhibitor. The gray zone represents the normal range. The horizontal broken line represents the limit of quantitation. The horizontal line of Fig. 2d indicates a C1-inhibitor activity level of 50%, which is stated in the diagnostic criteria (12). HAE: hereditary angioedema, Mast-AE: mast cell-mediated angioedema, C1-INH: C1-inhibitor

dreds of different heterozygous mutations of C1-INH have been described in a database (HAEdb, <http://hae.enzim.hu>), Japanese investigators are now going to perform a genetic analysis of a nationwide registration system that was established by The Japanese Association for Complement Research.

The AE attacks occurred in characteristic locations in both groups. In the HAE group, a history of AE in the extremities was the most common location of subcutaneous AE (80.4%). A previous per-patient analysis also reported that the extremities were the most affected parts in subcutaneous skin lesions among 209 HAE patients (15). The lips and eyelids were a common location in the Mast-AE group, which is consistent with mast cell degranulation being triggered by an antigen that enters these anatomical sites. On

the other hand, mucosal AE was not common in the Mast-AE group. Strikingly, the HAE patients developed life-threatening laryngeal edema and gastrointestinal AE. These severe attacks clearly pose obstacles in the daily lives of patients. In the future, we therefore need to understand the burden of illness in HAE patients with objective evaluation methods, such as the health quality of life (HRQoL) and the Dermatology Life Quality Index (DLQI) (16).

The clinical guidelines of the World Allergy Organization (WAO) recommend the measurement of the serum C4 level as the best specific screening test. The detection of C4 concentrations below the normal range shows 98% specificity in the diagnosis of HAE (2). Although our results showed that the specificity for a diagnosis of HAE was slightly lower (42 of 46 patients, 91.3%), the serum C4 level in 4 HAE

patients with a normal basal concentration did drop below the normal limit during AE attacks. Two of forty-one Mast-AE patients presented with low serum C4 levels, but had normal levels of immunoglobulins and CRP, and had no signs of autoimmune disease. Such patients may have genetic alterations at the C4 locus that disrupt their protein function (17). Titers of CH50 that were below the normal range were only observed in the HAE group but showed low diagnostic sensitivity (45.6%). In contrast to the measurement of CH50, a low C1-INH activity (<50% of normal) was observed in all of the patients in the HAE group and showed 100% specificity in the diagnosis of HAE. None of the patients in the Mast-AE group presented with low C1-INH activity. In our country, the measurement of the antigenic C1-INH levels is not currently approved by the Japanese health insurance system; thus, we measured the antigenic C1-INH levels at the patient's or research institution's expense, in some cases. Our results clearly indicated that the measurement of the C1-INH activity would be sufficient for making a diagnosis of HAE.

In conclusion, the characteristic features of AE-related medical history combined with the results of complement tests in HAE patients are highly informative when examined at the first consultation.

The authors state that they have no Conflict of Interest (COI).

Financial Support

This work was supported by JSPS KAKENHI Grant Number 26461493 and 26460654.

Acknowledgement

We wish to thank my colleagues in the Division of Nephrology, Department of Internal medicine, Juntendo University Faculty of Medicine, Tokyo, Japan and Nephrology unit, Saiyu Soka Hospital, Saitama, Japan

References

1. Zuraw BL. Hereditary angioedema. *N Engl J Med* **359**: 1027-1036, 2008.
2. Craig T, Pürsün EA, Bork K, et al. WAO guideline for the management of hereditary angioedema. *World Allergy Organ J* **5**: 182-199, 2012.
3. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. *Br J Dermatol* **161**: 1153-1158, 2009.
4. Psarros F, Koutsostathis N, Farmaki E, Speletas MG, Germenis AE. Hereditary angioedema in Greece: the first results of the Greek hereditary angioedema registry. *Int Arch Allergy Immunol* **164**: 326-332, 2014.
5. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. *Ann Allergy Asthma Immunol* **94**: 498-503, 2005.
6. Jolles S, Williams P, Carne E, et al. A UK national audit of hereditary and acquired angioedema. *Clin Exp Immunol* **175**: 59-67, 2014.
7. Ohsawa I, Honda D, Nagamachi S, et al. Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan. *Ann Allergy Asthma Immunol* **114**: 492-498, 2015.
8. Amar SM, Dreskin SC. Urticaria. *Prim Care* **35**: 141-157, vii-viii, 2008.
9. Bork K. Angioedema. *Immunol Allergy Clin North Am* **34**: 23-31, 2014.
10. Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. *J Am Acad Dermatol* **48**: 409-416, 2003.
11. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. *Ann Allergy Asthma Immunol* **109**: 395-402, 2012.
12. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. *J Allergy Clin Immunol* **114**: S51-S131, 2004.
13. Horiuchi T, Ohi H, Ohsawa I, et al. Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research - secondary publication. *Allergol Int* **61**: 559-562, 2012.
14. Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. *Allergy Asthma Clin Immunol* **9**: 29, 2013.
15. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. *Am J Med* **119**: 267-274, 2006.
16. Bygum A, Aygören-Pürsün E, Caballero T, et al. The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology. *BMC Dermatol* **12**: 4, 2012.
17. Hauptmann G, Goetz J, Uring-Lambert B, Grosshans E. Component deficiencies: 2. The fourth component. *Prog Allergy* **39**: 232-249, 1986.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).